Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executive leadership team will participate at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 5:15 p.m. ET.

A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.

About Catalent

Catalent, Inc., is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year.

Investor Contact: Paul Surdez, Catalent, Inc. (732) 537-6325 investors@catalent.com

Catalent (NYSE:CTLT)
過去 株価チャート
から 12 2024 まで 1 2025 Catalentのチャートをもっと見るにはこちらをクリック
Catalent (NYSE:CTLT)
過去 株価チャート
から 1 2024 まで 1 2025 Catalentのチャートをもっと見るにはこちらをクリック